Table 3.

Comparison of systemic symptoms between and within the vitamin D (n=54) and placebo (n=53) groups from baseline to week 8 after the intervention

	Baseline	Week 4	Week 8	P-value 1a)	P-value 2b)
Nausea/vomiting
Vit D	2 (1, 3)	2 (1, 3)	2 (1, 2)	0.773	<0.001c)
Placebo	2 (1, 3)	2 (1, 3)	2 (1, 3)	>0.999	>0.999
P-value 3d)	>0.999	0.761	>0.999
Diarrhea
Vit D	0 (0, 1)	0 (0, 1)	0 (0, 1)	>0.999	0.040c)
Placebo	0 (0, 1)	0 (0, 1)	0 (0, 1)	0.692	>0.999
P-value 3d)	>0.999	0.975	0.858
Headache
Vit D	1 (0.2, 2)	1 (0, 2)	1 (0, 2)	0.037c)	< 0.001c)
Placebo	1 (1, 2)	1 (1, 2)	1 (1, 2)	>0.999	>0.999
P-value 3d)	0.636	0.730	0.180
Fatigue
Vit D	2 (1, 3)	2 (1, 3)	2 (1, 2)	0.026c)	0.002c)
Placebo	2 (1, 3)	2 (1, 3)	2 (1, 3)	>0.999	>0.999
P-value 3d)	0.447	0.72	0.884
Total score
Vit D	5.5±2.3	5.3±2.3	4.7±2.2	0.01c)	<0.001c)
Placebo	5.2±2.6	5.1±2.6	5.2±2.5	0.848	0.484
P-value 3d)	0.485	0.531	0.451

Values are presented as mean±standard deviation or median (interquartile range 25%, 75%). 0=no symptom, 1=mild, 2=moderate, and 3=severe symptom.

^a)Wilcoxon signed-rank test, week 4 vs. baseline, corrected based on the Holm-Bonferroni method;

^b)Wilcoxon signed-rank test, week 8 vs. baseline, corrected based on the Holm-Bonferroni method;

^c)Indicating a statistically significant difference;

^d)Mann-Whitney U test, corrected based on the Holm-Bonferroni method.